Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2014 3
2016 1
2017 2
2018 6
2019 12
2020 9
2021 12
2022 8
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer.
Nishii K, Ohashi K, Tomida S, Nakasuka T, Hirabae A, Okawa S, Nishimura J, Higo H, Watanabe H, Kano H, Ando C, Makimoto G, Ninomiya K, Kato Y, Kubo T, Ichihara E, Hotta K, Tabata M, Toyooka S, Udono H, Maeda Y, Kiura K. Nishii K, et al. Among authors: makimoto g. Cancer Immunol Res. 2022 Sep 1;10(9):1111-1126. doi: 10.1158/2326-6066.CIR-21-0751. Cancer Immunol Res. 2022. PMID: 35802887 Free article.
PD-1 blockade augments CD8+ T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancer.
Nakasuka T, Ohashi K, Nishii K, Hirabae A, Okawa S, Tomonobu N, Takada K, Ando C, Watanabe H, Makimoto G, Ninomiya K, Fujii M, Kubo T, Ichihara E, Hotta K, Tabata M, Kumon H, Maeda Y, Kiura K. Nakasuka T, et al. Among authors: makimoto g. Lung Cancer. 2023 Apr;178:1-10. doi: 10.1016/j.lungcan.2023.01.018. Epub 2023 Feb 1. Lung Cancer. 2023. PMID: 36753780
Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
Ando C, Ichihara E, Nishi T, Morita A, Hara N, Takada K, Nakasuka T, Watanabe H, Kano H, Nishii K, Makimoto G, Kondo T, Ninomiya K, Fujii M, Kubo T, Ohashi K, Matsuoka KI, Hotta K, Tabata M, Maeda Y, Kiura K. Ando C, et al. Among authors: makimoto g. Cancer Sci. 2023 Nov;114(11):4343-4354. doi: 10.1111/cas.15958. Epub 2023 Sep 15. Cancer Sci. 2023. PMID: 37715310 Free PMC article.
CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Hara N, Ichihara E, Kano H, Ando C, Morita A, Nishi T, Okawa S, Nakasuka T, Hirabae A, Abe M, Asada N, Ninomiya K, Makimoto G, Fujii M, Kubo T, Ohashi K, Hotta K, Tabata M, Maeda Y, Kiura K. Hara N, et al. Among authors: makimoto g. Transl Lung Cancer Res. 2023 Oct 31;12(10):2098-2112. doi: 10.21037/tlcr-23-99. Epub 2023 Oct 26. Transl Lung Cancer Res. 2023. PMID: 38025818 Free PMC article.
Identification of targetable kinases in idiopathic pulmonary fibrosis.
Higo H, Ohashi K, Tomida S, Okawa S, Yamamoto H, Sugimoto S, Senoo S, Makimoto G, Ninomiya K, Nakasuka T, Nishii K, Taniguchi A, Kubo T, Ichihara E, Hotta K, Miyahara N, Maeda Y, Toyooka S, Kiura K. Higo H, et al. Among authors: makimoto g. Respir Res. 2022 Feb 7;23(1):20. doi: 10.1186/s12931-022-01940-y. Respir Res. 2022. PMID: 35130915 Free PMC article.
56 results